Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines

Research output: Contribution to journalArticle

300 Scopus citations

Abstract

NMDA and non-NMDA (AMPA/kainate) antagonists have potential in the treatment of a diverse group of neurological disorders associated with excessive activation of excitatory amino acid receptors. Here Michael Rogawski reviews recent progress in the development of therapeutically useful NMDA receptor channel blockers and a new class of selective AMPA/ kainate receptor antagonists, the 2,3-benzodiazepines. Research on these novel noncompetitive excitatory amino acid antagonists has opened promising new avenues for the development of drugs to treat epilepsy, ischaemia, neuro-degeneration and Parkinson's disease.

Original languageEnglish (US)
Pages (from-to)325-331
Number of pages7
JournalTrends in Pharmacological Sciences
Volume14
Issue number9
DOIs
StatePublished - 1993
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Fingerprint Dive into the research topics of 'Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines'. Together they form a unique fingerprint.

  • Cite this